서브메뉴
검색
Overcoming Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma: Micro- and Nanotechnology-Based Drug Delivery as Novel Therapeutic Strategies
Overcoming Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma: Micro- and Nanotechnology-Based Drug Delivery as Novel Therapeutic Strategies
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20250211153036
- ISBN
- 9798346758570
- DDC
- 610
- 저자명
- Li, Xiyao.
- 서명/저자
- Overcoming Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma: Micro- and Nanotechnology-Based Drug Delivery as Novel Therapeutic Strategies
- 발행사항
- [Sl] : University of California, Los Angeles, 2024
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2024
- 형태사항
- 119 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 86-06, Section: B.
- 주기사항
- Advisor: Li, Song.
- 학위논문주기
- Thesis (Ph.D.)--University of California, Los Angeles, 2024.
- 초록/해제
- 요약Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide. For most HNSCC patients with locally advanced disease, platinum-based drugs, especially cisplatin, remain the gold standard to reduce the risk of recurrence and improve survival rate. Drug resistance, however, is the main issue obstructing the optimum cisplatin therapeutic efficiency. In this dissertation research, two auxiliary systems were designed to overcome the cisplatin resistance in HNSCC. The first system loaded a small molecule drug with high therapeutic efficacy into polymer microparticles. Upon the intratumoral injection through microneedle, a local and sustained release was achieved, leading to suppressed proliferation, inhibited migration, and promoted apoptosis of cancer cells. The second system involves the design of a novel enzyme delivery system to target tumor microenvironment, which not only reduces cancer cell viability, migration, and invasion, but also activates immune response. The strategies described in this dissertation research can be extended to other small molecule drugs or therapeutic proteins for cancer therapies beyond cisplatin-resistant HNSCC, providing a platform for more effective cancer therapy.
- 일반주제명
- Bioengineering
- 일반주제명
- Cellular biology
- 일반주제명
- Oncology
- 키워드
- Cancer therapy
- 기타저자
- University of California, Los Angeles Bioengineering 0288
- 기본자료저록
- Dissertations Abstracts International. 86-06B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008250123s2024 us c eng d■001000017164724
■00520250211153036
■006m o d
■007cr#unu||||||||
■020 ▼a9798346758570
■035 ▼a(MiAaPQ)AAI31637946
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a610
■1001 ▼aLi, Xiyao.
■24510▼aOvercoming Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma: Micro- and Nanotechnology-Based Drug Delivery as Novel Therapeutic Strategies
■260 ▼a[Sl]▼bUniversity of California, Los Angeles▼c2024
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2024
■300 ▼a119 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 86-06, Section: B.
■500 ▼aAdvisor: Li, Song.
■5021 ▼aThesis (Ph.D.)--University of California, Los Angeles, 2024.
■520 ▼aHead and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide. For most HNSCC patients with locally advanced disease, platinum-based drugs, especially cisplatin, remain the gold standard to reduce the risk of recurrence and improve survival rate. Drug resistance, however, is the main issue obstructing the optimum cisplatin therapeutic efficiency. In this dissertation research, two auxiliary systems were designed to overcome the cisplatin resistance in HNSCC. The first system loaded a small molecule drug with high therapeutic efficacy into polymer microparticles. Upon the intratumoral injection through microneedle, a local and sustained release was achieved, leading to suppressed proliferation, inhibited migration, and promoted apoptosis of cancer cells. The second system involves the design of a novel enzyme delivery system to target tumor microenvironment, which not only reduces cancer cell viability, migration, and invasion, but also activates immune response. The strategies described in this dissertation research can be extended to other small molecule drugs or therapeutic proteins for cancer therapies beyond cisplatin-resistant HNSCC, providing a platform for more effective cancer therapy.
■590 ▼aSchool code: 0031.
■650 4▼aBioengineering
■650 4▼aCellular biology
■650 4▼aOncology
■653 ▼aCancer therapy
■653 ▼aHead and neck squamous cell carcinoma
■653 ▼aPolymer microparticles
■690 ▼a0202
■690 ▼a0379
■690 ▼a0992
■690 ▼a0769
■71020▼aUniversity of California, Los Angeles▼bBioengineering 0288.
■7730 ▼tDissertations Abstracts International▼g86-06B.
■790 ▼a0031
■791 ▼aPh.D.
■792 ▼a2024
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17164724▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.
